

# **Mapping of Adenovirus of serotype 3 fibre interaction to desmoglein 2 revealed a novel 'non-classical' mechanism of viral receptor engagement**

Emilie Vassal-Stermann, Manon Mottet, Corinne N Ducournau, Frédéric Iseni, Charles Vragniau, Hongjie Wang, Chloe Zubieta, André Lieber, Pascal Fender

### **To cite this version:**

Emilie Vassal-Stermann, Manon Mottet, Corinne N Ducournau, Frédéric Iseni, Charles Vragniau, et al.. Mapping of Adenovirus of serotype 3 fibre interaction to desmoglein 2 revealed a novel 'non-classical' mechanism of viral receptor engagement. Scientific Reports, 2018, 8 (1), pp.8381. fold 10.1038/s41598-018-26871-x hal-01810699

## **HAL Id: hal-01810699 <https://hal.science/hal-01810699v1>**

Submitted on 23 Oct 2024

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# SCIENTIFIC REPERTS

Received: 2 February 2018 Accepted: 18 May 2018 Published online: 30 May 2018

# **Mapping of Adenovirus of serotype OPEN3 fbre interaction to desmoglein 2 revealed a novel 'non-classical' mechanism of viral receptor engagement**

**Emilie Vassal-S[t](http://orcid.org/0000-0003-2991-9937)ermann<sup>1</sup>, Manon Mottet<sup>®1</sup>, Corinne Ducournau<sup>1,2</sup>, Frédéric Iseni<sup>2</sup>, Charles Vragniau<sup>1</sup>, Hongjie Wang<sup>3</sup>, Chloe Zubieta<sup>4</sup>, André Lieber<sup>3</sup> & Pascal Fender<sup>1</sup>** 

**High-afnity binding of the trimeric fbre protein to a cell surface primary receptor is a common feature shared by all adenovirus serotypes. Recently, a long elusive species B adenovirus receptor has been identifed. Desmoglein 2 (DSG2) a component of desmosomal junction, has been reported**  to interact at high affinity with Human adenoviruses HAd3, HAd7, HAd11 and HAd14. Little is **known with respect to the molecular interactions of adenovirus fbre with the DSG2 ectodomain. By using diferent DSG2 ectodomain constructs and biochemical and biophysical experiments, we report that the third extracellular cadherin domain (EC3) of DSG2 is critical for HAd3 fbre binding. Unexpectedly, stoichiometry studies using multi-angle laser light scattering (MALLS) and analytical ultra-centrifugation (AUC) revealed a non-classical 1:1 interaction (one DSG2 per trimeric fbre), thus diferentiating 'DSG2-interacting' adenoviruses from other protein receptor interacting adenoviruses in their infection strategy.**

Adenoviruses (Ads) are a family of non-enveloped double-stranded DNA viruses infecting a wide variety of hosts including mammals. Infection occurs through a sequential two-step cell internalization process involving the binding of the adenovirus fbre protein to an attachment receptor followed by the interaction of the penton base protein with integrins that trigger endocytosis<sup>1</sup>. Different species of adenoviruses, including human adenoviruses, use distinct receptors for infection.

Human adenovirus serotypes (HAds) have been classified into seven species (A to G). The fibre of multiple serotypes from species A, C, D, E and F (*e*.*g*. serotypes 2, 4, 5, 9, 12, 15, 19, 31, 41) has been described to use the coxsackie and adenovirus receptor (CAR) as a primary attachment receptor<sup>2,3</sup>. However, species B adenoviruses use either CD46 or desmoglein-2 (DSG2) as a receptor<sup>4-6</sup>. For instance, HAd16, HAd21, HAd35 and HAd50 nearly exclusively use CD46 as a receptor whereas HAd3, HAd7, HAd11 and HAd14 share the newly identifed DSG2 receptor. Moreover, HAd11 and to a lesser extend HAd3 interact with both CD46 and DSG2 based on receptor density at the cell surface<sup>6,7</sup>. The identification of this new DSG2 receptor was made using a HAd3 virus-like-particle (VLP) named Penton Dodecahedron (Pt-Dd). Tis particle is composed of twelve penton bases interacting together in a symmetric manner with twelve fbres protruding from the particle surface. Pt-Dd is produced during the natural Ad3 replication cycle but can also be recombinantly expressed using the baculovirus system<sup>8,9</sup>. In agreement with previous observations made for CAR and CD46, the interaction of Pt-Dt with DSG2 involves specifically the distal globular part of the adenovirus fibre called the knob domain $10-13$ .

<sup>1</sup>Institut de Biologie Structurale (IBS), Université Grenoble Alpes, CNRS, CEA, 71 Avenue des Martyrs, 38042, Grenoble, France. <sup>2</sup>Unité de Virologie, Institut de Recherche Biomédicale des Armées, BP 73, 91223, Brétigny-sur-Orge Cedex, France. <sup>3</sup>University of Washington, Department of Medicine, Division of Medical Genetics, Box 357720, Seattle, WA, 98195, USA. <sup>4</sup>Laboratoire de Physiologie Cellulaire et Végétale, Biosciences and Biotechnology Institute of Grenoble, UMR5168, CNRS/CEA/INRA/UGA, 17 Rue des Martyrs, 38054, Grenoble, France. Correspondence and requests for materials should be addressed to A.L. (email: [lieber00@u.washington.edu\)](mailto:lieber00@u.washington.edu) or P.F. (email: [pascal.](mailto:pascal.fender@ibs.fr) [fender@ibs.fr](mailto:pascal.fender@ibs.fr))





**Figure 1.** General characterization of the DSG2 full length ectodomain. (**A**) Schematic representation of recombinant DSG2 containing the four extracellular subdomains (EC1-4) and a C-terminal His tag. (**B**) InstantBlue-stained SDS-PAGE of purifed recombinant DSG2 EC1-4; full-length gel is presented in Supplementary Figure S1. (**C**) MALDI-TOF mass spectrum of DSG2 EC1-4. (**D**) SPR analysis of the interaction of PtDd with immobilized recombinant DSG2 EC1-4. PtDd was injected at diferent concentrations ranging from 1.2 to 300nM.

DSG2 is mainly found in epithelial cells but also in cardiomyocytes where mutations are responsible for arrhythmogenic right ventricular dysplasia and cardiomyopathy<sup>14</sup>. In desmosomes, DSG2 receptors are in a strong heterophilic interaction with Desmocollin 2 (DSC2)<sup>15</sup>. Both DSC2 and DSG2 belong to the type-1 transmembrane proteins of the cadherin superfamily and interact together through their distal extracellular cadherin domain, called EC1. The whole ectodomain of DSG2 is composed of four extracellular cadherin domains, EC1 to EC4, and a domain proximal to the membrane, the Extracellular Anchor (EA). The crystallographic structure of DSG2 has recently been published16. Each EC domain carries N-glycosylations with EC4 having an extra O-glycosylation. The linearity of DSG2 ectodomain is drastically disrupted by a 100° hinge between EC3 and EC4.

Interestingly, DSG2 expression can vary in diferent cancer types. For instance, overexpression of this receptor has been reported in non-small cell lung cancer or in squamous cell carcinoma correlating with a high risk of metastasis<sup>17,18</sup>. Indeed, cancer cells maintain strong intercellular junctions such as tight junctions, adherens junctions, gap junctions and desmosomes, which limit the diffusion of drugs in tumours<sup>19,20</sup>. It has been described that the simultaneous interaction of several knob domains with DSG2, a situation found in the whole virus or in Pt-Dd, which presents 12 fbres per particle, triggers intracellular signalling, and in turn cell membrane remodelling<sup>9,21,22</sup>. This property has been exploited to develop "junction openers" (JOs) which enhance the efficacy of cancer drug compounds such as MAbs or  $\text{DOXIL}^{\otimes 23,24}$ . The binding of JOs to DSG2 receptor is responsible for transient epithelial-to-mesenchymal transition (EMT) and DSG2 shedding6,25,26, which partially unlocks these junction padlocks.

Since Adenovirus is the most used vector in human gene therapy trials, deciphering the molecular basis of 'DSG2-interacting' HAd-fbres binding to DSG2 may create a new basis for the development of next-generation therapeutics. Indeed, rational design of mutated fibre for detargeting/retargeting could be developed for DSG2-interacting oncolytic adenovectors<sup>27-29</sup>. Moreover, beside this vector-based approach, a better comprehension of the HAd/DSG2 interaction would enable the design of improved JO molecules, thus potentiating the therapeutic efficacy of approved chemotherapeutic drugs or therapeutic MAbs. In the present work, we have mapped the critical EC domain required for HAd3 binding to DSG2. In addition, based on the stoichiometry of the measured interactions, a non-classical mechanism of HAd3 fibre binding to DSG2 is reported. This interaction is a novel binding strategy not observed in other adenovirus/protein receptor complexes such as Ad/CAR and Ad/CD46.

#### **Results**

**Production of glycosylated EC1-4 desmoglein 2.** To ensure that DSG2 ectodomain can be produced as a functional protein, we frst expressed the whole ectodomain carrying the four cadherin domains (EC1-4) with a C-terminal His-Tag (Fig. 1A). To as closely as possible mimic what is found at the cell surface, we used the mammalian HEK-293 F expression system to produce secreted EC1-4. Tis resulted in the production of a highly glycosylated native protein. Afer purifcation, the protein migrated on SDS-PAGE gel about 10 KDa above its predicted mass (51 KDa), refecting the presence of glycosylation (Fig. 1B). Furthermore, the molecular mass was determined more accurately by MALDI TOF and a peak around 60.5 kDa confrmed the presence of more than 9 kDa of glycans, in accordance with recently published results<sup>16</sup> (Fig. 1C). Since we have previously shown that HAd3 recombinant penton-dodecahedron (Pt-Dd), a dodecahedric particle with twelve fbres, interacts with a commercial DSG2 by surface plasmon resonance (SPR) experiments<sup>6</sup>, the functionality of recombinant DSG2



**Figure 2.** Mapping of EC domains required for fbre binding (**A**) Schematic representation of the diferent recombinant DSG2 constructs EC1-4, EC1-3 and EC2-3. (**B**) Gel fltration based co-elution experiments. Size exclusion chromatography analysis of Ad3K co-incubated with the diferent constructs demonstrates a shift of elution to smaller retention volumes in each case thus reflecting an increased molecular weight. This is an agreement with a complex formation between DSG2 and Ad3K. (**C**) 10 or 4–20% SDS-PAGE analysis of the peak fractions aligned to its corresponding chromatogram show the presence of both Ad3K and DSG2 construct (as indicated) in the shifed peak confrming the formation of a complex.

EC1-4 was checked using the same experimental set-up. In contrast to the fbreless 'base-dodecahedron' particles (Bs-Dd) (not shown), Pt-Dd interacted with DSG-2 in a dose-dependent manner at nanomolar concentrations (Fig. 1D).

**Mapping of DSG2 binding domains.** *Co-elution chromatography studies*. We next attempted to identify DSG2 cadherin domains that are critical for recombinant Ad3 fbre knob (Ad3K) binding by using co-elution chromatography studies. We compared the chromatographic profles of purifed recombinant DSG2 domains (Fig. 2A) in the presence or absence of Ad3K by size exclusion chromatography. Unbound DSG2 EC1-4 eluted as a single peak with an elution volume of 12.8mL whereas DSG2 EC1-4 in complex with Ad3K eluted earlier at 10.9ml, suggesting complex formation (Fig. 2B, lef panel). SDS-PAGE analysis of the peak 1 (10 to 12mL) confrmed co-elution of Ad3K and DSG2 EC1-4 (band below 34 and above 55kDa respectively in Fig. 2C). Fractions corresponding to peak 2 (12 to 14mL) clearly showed an excess of DSG2 EC1-4.

To test the involvement of the EC4 domain in DSG2 binding, we generated an EC4-deleted DSG2, named DSG2 EC1-3 by transient transfection in HEK-293 F (Fig. 2A, middle panel). Co-elution chromatography experiments showed that DSG2 EC1-3 bound efficiently to Ad3K (Fig. 2B, middle panel). This suggests that the EC4 domain does not contribute to binding with Ad3K. We also produced DSG2 in which the EC1 and the EC4 domains were both deleted (EC2-3) (Fig. 2A, right panel). A similar elution profle was observed, with a frst peak corresponding to the complex EC2-3/Ad3K (11 to 13mL) and a second peak corresponding to an excess of EC2-3 (13 to 15mL). Tese results indicate that, although the EC1 domain is needed for the strand-swap mechanism of adhesive binding in classical cadherins, it is not essential for optimal Ad3K binding. The EC2-3 cadherin ectodomain fragment is thus sufficient for the interaction with Ad3K.

*Minimal DSG2 domain determination by Surface Plasmon Resonance (SPR).* The goal of this experiment was to more precisely distinguish the respective roles of EC2 and EC3 in the interaction with Ad3K. Despite extensive efforts to produce EC3 or EC2 constructs in the HEK-293 system, we did not manage to express these domains alone as soluble proteins. We then decided to split the DSG2 ectodomain in EC1-EC2 and EC3-EC4 (Fig. 3A). Of note, the recombinant DSG2-cadherin EC3-4 fragment was produced in bacteria and thus lacks glycosylation.

The concentration-dependent binding of Pt-Dd to immobilized DSG2 EC3-4 (Fig. 3B) indicates that EC3 is sufficient to mediate the interaction. Conversely, Pt-Dd showed no interaction at all to immobilized DSG2 EC1-2 (Fig. 3C). EC3 domain is thus critical for Ad3K binding and since SPR is a very sensitive method to detect even weak interactions, this also means that EC2 alone is not able to mediate this interaction. Moreover, the surface was regenerated by injection of 10 mM EDTA, indicating that the EC3 cadherin domains must be loaded with calcium to enable this specifc interaction.

Altogether, these data demonstrate that EC3 domain is specifically required for fibre binding and that the lack of glycosylation in these constructs produced in *E*. *coli* did not impair binding thus supporting the de-glycosylation experiments shown in Supplementary Fig.S1. Since these post-translational modifcations of DSG2 are not required for the interaction it can be concluded that Ad3 fbre knobs interacts with the EC3 polypeptide in a calcium dependent manner and not with glycans.



**Figure 3.** Determination of the interactions by EC2 or EC3 by SPR. (**A**) Schematic representation of recombinant DSG2 constructs EC1-2 and EC3-4. (**B**) SPR analysis of the interaction of PtDd with immobilized DSG2 EC3-4. Pt-Dd was injected at diferent concentrations ranging from 0.3nM to 14.0nM. (**C**) Same analysis as in (**B**) with DSG2 EC1-2.



**Figure 4.** Prokaryotic coexpression of the complex. (**A**) Schematic representation of DSG2/Ad3K pETDuet vectors. RBS: Ribosome Binding Site; MBP: Maltose Binding Protein tag. (**B**) Afnity purifcation of recombinant HisAd3K and associated proteins from *E*. *coli* extracts. pETDuet vectors expressing His-Ad3K and MBP-EC2-3 or MBP-EC3 were grown and induced with IPTG. Cells were lysed and insoluble material was removed by centrifugation. His Ad3K was purifed by nickel afnity chromatography as described in Experimental Procedures. Sample contents from elution fractions 1-8 were analyzed by SDS-PAGE. Left panel shows the MBP-EC2-3 coelution with His-Ad3K, right panel shows the same experiment with MBP-EC3.

**Co-expression experiments.** In order to provide additional support for these results and to further characterize the complex, we co-expressed the N-terminal His-tagged Ad3K (His-Ad3K) together with DSG2 EC2-3 or DSG2 EC3 in bacteria. Given that expression of DSG2 in bacteria showed relatively low yields of soluble protein, we fused the DSG2 domains to the Maltose Binding Protein (MBP) to increase solubility with an upstream Tobacco Etch Virus (TEV) protease cleavage site (Fig. 4A) to allow the subsequent removal of the MBP tag prior to biophysical studies.

Lysates of either His-Ad3K and MBP-DSG2 EC2-3 or His-Ad3K and MBP-DSG2 EC3 were loaded onto a His GraviTrap column and eluted with imidazole. SDS-PAGE analysis showed that both MBP-DSG2 EC2-3 (theoretical mass 69.9kDa) and MBP-DSG2 EC3 (theoretical mass 57.3kDa) co-eluted with His-Ad3K (theoretical mass 23 kDa), demonstrating complex formation between the two proteins (Fig. 4B, left and right panels, respectively). This result indicates that EC3 domain alone is sufficient to interact with Ad3K and that EC3 is the critical domain of DSG2 targeted by the viral protein.

**TEM imaging of the complex after MBP removal.** The stability of these two complexes after MBP removal was then investigated. Afer TEV protease treatment, complexes were loaded again on the His GraviTrap column and then purifed by Size Exclusion Chromatography (SEC). Digested DSG2 EC2-3 (theoretical mass 27.8 kDa) and His-Ad3K still co-eluted during this second purification steps (Fig. 5A), reflecting the stability of



**Figure 5.** Purifcation and electron microscopy of MBP-free Ad3K+EC2-3 complex. (**A**) InstantBlue-stained SDS-PAGE of the purifed Ad3K and Ad3K+EC2-3 complex afer MBP removal. Full-length gel is presented in Supplementary Figure S2. (**B**) Negative-staining electron microscopy analysis. Lef panel: Electron micrograph of Ad3K stained with uranyl acetate. Right panel: Electron micrograph of Ad3K in complex with EC2-3 stained with uranyl acetate. Representative class averages are shown on the galleries to the right of each micrograph.



**Figure 6.** Stoichiometry analysis of the Ad3K + EC2-3 complex. (A) Molecular mass determination by SEC-MALLS. Overlay of SEC elution profles of Ad3K (grey line) and Ad3K in complex with EC2-3 (black line). The lines in green or blue represent the average molecular weight of the major  $Ad3K$  and  $Ad3K+EC2-3$ species calculated by using the light-scattering measurements (scale on the right y axis). (**B**) Analytical ultracentrifugation (AUC) analysis. Normalized  $c(s)$  distribution curves calculated from the raw data using SEDFIT are shown for Ad3K (in blue) and for Ad3K in complex with EC2-3 (in green). The resulting sedimentation coefficients are indicated for the main peaks.

this MBP-free complex. Conversely, no co-elution was observed for Ad3K in complex with EC3 domain alone afer MBP removal (not shown). Altogether, this data indicates that (*i*) EC3 is the domain targeted by Ad3K for binding (*ii*) complex formation is successful by co-expression of His-Ad3K and receptor constructs in bacteria and (*iii*) EC3 required a stabilizing peptide such as MBP or the EC2 domain to be functional. Based on these data, EC2-3 was used for the next experiments aiming at investigating the oligomeric status of the complex.

The homogeneity of Ad3K-EC2-3 complex was then studied by negative stain electron microscopy and compared to Ad3K alone. While both samples appeared homogenous, the particles corresponding to the complex were distinct from Ad3K alone (Fig. 5B). The shape was altered by the presence of the receptor on the trimeric knob. Since these objects are very small, they were subjected to class averages (representative classes are enlarged on the right of the corresponding micrographs). As expected, Ad3K alone gave triangular shapes whereas the three-fold symmetry was lost when receptor was added. Neither triangular nor hexagonal shapes were found for the latter, suggesting that the stoichiometry might be diferent from that reported for other adenovirus serotypes interacting with proteinaceous receptors (*i*.*e*. three receptors per trimeric knob)11,12. To confrm this, additional biophysical experiments were performed.

**Stoichiometry determination.** *Multi-Angle Laser Light Scattering (MALLS experiments)*. To investigate the oligomeric state of the His-Ad3K/DSG2 EC2-3 complex in solution, SEC coupled to Multi-Angle Laser Light Scattering (SEC-MALLS) was performed to estimate its molecular weight as compared to His-Ad3K alone (Fig. 6A). The data indicated a molecular weight of ∼66 kDa with a 1.3% fitting error and a polydispersity of 1.000 for the trimeric His-Ad3K (theoretical mass is 69 kDa) and a molecular weight of ∼103 kDa with a 1.8% ftting error and a polydispersity of 1.000 for the His-Ad3K/DSG2 EC2-3 complex. Tis latter value is consistent with a single monomer of DSG2 EC2-3 binding a trimer of His-Ad3K (expected mass 96 kDa) and is too low to refect two or three receptor molecules binding a trimer of His-Ad3K (expected mass 120 kDa and 144 kDa, respectively).

*Sedimentation Equilibrium- Analytical Ultra Centrifugation (SE-AUC experiments).* Sedimentation equilibrium analytical ultra-centrifugation (SE-AUC) was then used to further elucidate the stoichiometry of the complex in solution (Fig. 6B). Data obtained by SE-AUC for His-Ad3K were in good agreement with those from SEC-MALLS, showing a sedimentation coefficient of 4.41 S corresponding to a mass of approximately 69.6 kDa, which are consistent with the predicted masses of the trimeric knob.

With respect to the His-Ad3K/DSG2 EC2-3 complex, AUC revealed one major peak representing 72% of the signal, with sedimentation coefficients of 5.40 S corresponding to a mass of approximately 95.1 kDa. This value is in agreement with the one receptor per trimeric knob scenario (expected mass 96 kDa). Tis peak was followed by a shoulder representing 19% of the signal, with sedimentation coefficients of 7.34 S, corresponding to a mass of approximately 132.4 kDa. While it is difficult to attribute this minor peak, its sedimentation coefficient rules out a three receptor per trimeric knob scenario. By combining the SEC-MALLS and SE-AUC data, it can be concluded that the main species in solution corresponds to a homogeneous complex made of one trimeric knob bound to a single EC2-3 receptor.

#### **Discussion**

Intuitively, one can imagine that viruses evolve to interact with well-displayed receptors at the apical side of epithelial cells. Paradoxically, a number of viruses have been reported to interact with poorly accessible receptors hidden at the cell-cell junction. Among them, both enveloped and non-enveloped viruses have been identifed such as Measles Virus, Herpes Simplex Virus, Hepatitis C Virus, Reovirus and Cocksackievirus (for review, see Mateo *et al*. 30). Adenoviruses are another example of this since the frst identifed and most common adenovirus receptor, CAR, is a member of tight junctions<sup>2,51</sup>. In our work, we have investigated the molecular interaction of the Human species B adenovirus, HAd3, to the junctional component, DSG2. This latter is naturally found in heterophilic interaction with desmocollin2 (DSC2) to form desmosomal junctions between epithelial cells<sup>32</sup>. DSG2 expands the repertoire of cell-cell junction receptors that can be targeted by adenovirus.

The structure of DSG2 has been recently solved by X-ray crystallography revealing that N-glycosylations are linked to each EC domain, thus confirming bio-informatics predictions<sup>16</sup>. Based on our current study, we have expressed DSG2 ectodomain in mammalian cells in order to preserve the glycosylation pattern of the protein. DSG2 constructs were cloned in the pHLsec plasmid enabling their maturation in the endoplasmic reticulum and Golgi apparatus before being secreted in the medium. As expected, the whole ectodomain construct (EC1-4), with a theoretical MW of 51 kDa, was glycosylated and ran as a relatively difuse band in SDS-PAGE (Fig. 1B). Mass spectroscopy analysis confrmed the numerous post-translational modifcations of this construct as refected by the wide peak displaying an average mass of 60.5 kDa (Fig. 1C). Tis highly-glycosylated DSG2 ectodomain was functional as shown by the SPR experiments in which increasing amounts of Pt-Dd were injected over the immobilized receptor (Fig. 1D). Of note, sensorchip regeneration was performed with EDTA, refecting that calcium was required for the proper folding of EC1-4.

The atomic structure of the DSG2 ectodomain has also revealed that the protein can make homophilic interactions via its distal EC1 domain at least under crystallisation conditions<sup>16</sup>. However, this putative dimerization of DSG2 is not a requirement for Ad binding, since EC1-containing (EC1-4, EC1-3) as well as EC1-devoid constructs (EC2-3) were equally able to form a stable complex with Ad3K as demonstrated by our SEC experiments (Fig. 2B). Since EC2-3 carried two cadherin domains shared by all three constructs, we tried to defne more precisely which of these extracellular domains was critical for the interaction with Ad3K. Tus, EC1-2 and EC3-4 constructs were produced and characterized by SPR for Ad3K binding. No binding was detected for EC1-2 by this sensitive method indicating that domain 2 was not sufficient to enable adenovirus binding and suggested that EC3 is the critical domain required for this interaction. Tis observation was confrmed by the SPR experiments using the EC3-4 construct, which showed a dose-dependent binding of Ad3K (Fig. 3B). Taken together, EC3 is the main domain of DSG2 targeted by HAd3. Tis result is in agreement with an experiment described by Wang et *al*., which reported that 6D8 and 8E5 MAbs (directed against EC3 and EC3-4 respectively) were able to decrease by 20 to 40% HAd3 binding to the cell surface (and up to 65% when used in combination) while other MAbs directed against EC1 or EC2 did not compete at all<sup>6</sup>.

Since the EC3-4 construct produced in a prokaryotic system was functional (Fig. 3B), this allowed prokaryotic coexpression of Ad3K with diferent DSG2 constructs. In a frst attempt, EC2-3 was cloned in fusion to a MBP tag and co-expressed in pETDuet vector with 6X His-tagged Ad3K. Immobilized Metal-Afnity Chromatography (IMAC) purification clearly showed that MBP-EC2-3 was retained by the His-tagged Ad3K (Fig. 4B) thus demonstrating that glycosylation is not required for the Ad3K-DSG2 interaction as further demonstrated by the de-glycosylation experiments shown in Supplementary Fig. S1. A similar experiment was performed with the EC3 domain alone fused to MBP and gave the same result, confirming that EC3 is sufficient to make a stable complex with Ad3K. To further characterise the complex, MBP was removed *via* a TEV cleavage site. Removal of MBP did not afect EC2-3/Ad3K complex formation as seen by both SDS-PAGE (Fig. 5A) and electron microscopy (Fig. 5B). However, complexes with only EC3 were unstable upon MBP cleavage (not shown). Tis result indicates that even if EC3 is sufficient for Ad3K binding, it likely needs to be fused to a solubilizing polypeptide such as EC2 or MBP, at least in prokaryotic expression systems. In the absence of these polypeptides, the potential 'chaperone-like' activity played by Ad3K co-expressed with EC3 alone is not sufficient to stabilize the complex.

Since MBP tends to multimerize, it is necessary to remove this tag to unambiguously analyse the stoichiometry of the complex. To study the stoichiometry, Ad3K/MBP-EC2-3 complex was purifed by IMAC, cleaved by TEV protease and MBP-free Ad3K/EC2-3 complex was recovered using a second IMAC as shown in Fig. 5A. Tis latter complex was then analysed by MALLS (Multi-Angle Laser Light Scattering), which enables the determination of the molecular weight of molecules or complex separated by SEC. Molecular weight and dispersity were assessed from the main peak (Fig. 6A) indicating that the complex was monodisperse (1.000) with an estimated mass of 103kDa. Since Ad3K is 69kDa and EC2-3 is 27kDa, we can exclude the presence of two or more receptors

per trimeric fibre knob. The most likely explanation for a complex at 103 kDa is that only one receptor molecule is bound per trimeric knob (theoretical MW = 96 kDa). The 7% deviation is slightly above the 5% interval of confdence usually accepted with this technique. To support or reject this model an Analytical Ultra-Centrifugation (AUC) experiment was then performed. The Ad3K alone and Ad3K/EC2-3 complexes were run at two different concentrations. The shift between those two species was obvious with Ad3K/EC2-3 displaying a sedimentation coefficient of 5.40 S instead of 4.41 S for the fibre knob alone (Fig.  $6B$ ). More importantly, MW calculations from AUC data enabled the calculation of a molecular mass of 69.6 kDa for Ad3K and 95.1 kDa for the complex, thus confrming that only one receptor is bound per trimeric fbre knob. Tis observation represents a signifcant breakthrough in Adenovirus attachment to a protein cellular receptor. Indeed, up to now, the fbre of other adenovirus species described to interact with CAR, CD46 or sialic acid have been reported to exhibit three receptor binding sites per trimeric fibre<sup>11,12,33</sup>. The only notable exception to date lies on the interaction of HAd37 to the GD1a glycan<sup>34</sup> for which a 1:1 (fibre:GD1a) interaction has also been reported. This disialylated hexasaccharide molecule carries two sialic acids which occupy two out of the three binding sites available in the trimer. Our fnding for HAd3 binding to DSG2 clearly suggests that DSG2-interacting-Ads use a diferent strategy of attachment to the receptor and/or spreading as compared to other HAds. It is of note that free trimeric HAd2-fbre has been reported to disrupt CAR-mediated intercellular adhesion on its own<sup>31</sup>. In contrast, HAd3 fibre alone is not able to disrupt desmosomes and must be displayed on a scafold of 12 penton bases (*i*.*e* virion or Pt-Dd) to trigger cell remodelling<sup>9,22</sup>. Even though our work has been performed with soluble DSG2 constructs, this may suggest that the 1:1 ratio (fibre:receptor) does not enable sufficient signal transduction in DSG2 integrated into the membrane and that dodecamerisation of the fbre in DSG2-interacting-HAds has evolved to overcome this limitation. Taken together, these results provide a molecular basis for Ad3K-DSG2 interactions and suggest that designing of HAd3-based therapeutics should take into account the novel stoichiometry of HAd3-receptor interactions. Increasing the numbers of Ad3Ks displayed on the Junction-Opener (JO) therapeutic is an attractive way to optimise junction-opening efficacy. Moreover, this biochemical and biophysical work provides a foundation for structural characterization of Ad3K in complex with DSG2 by either protein crystallographic or electron microscopy methods. As a longer-term goal, the identifcation of the residues from both partners involved in the interaction will allow the design of new HAd3-derived vectors with modifed DSG2 tropism by incorporating rationally designed mutations in the HAd3 fbre knob.

#### **Methods**

**Mammalian protein production.** *Construction of plasmids expressing His-DSG2*. Coding sequence for human DSG2-cadherin domains EC1-4 (Ala50–Asp494 of the native protein, Swiss-Prot: Q14126.2) was amplified by PCR from the plasmid LV41-DSG2<sup>35</sup> and cloned into the expression vector pHL-sec using the restriction sites AgeI/KpnI. pHL-sec was a gif from Edith Yvonne Jones (Addgene plasmid # 99845). It contains a Kozak sequence, a secretion signal sequence and a C-terminal hexa histidine tag<sup>36</sup>. Coding sequences for human DSG2cadherin domains EC1-3, EC2-3 and EC3 (respectively Ala50–Ile386, Val149-Ile386, Ile262-Ile386 of the native protein) were amplifed by PCR from the plasmid pHL-sec-DSG2 EC1-4 and inserted into pHL-sec using the restriction sites AgeI/KpnI.

*Transient transfection.* For protein expression, human embryonal kidney HEK293 F cells were maintained in FreeStyle™ 293 Expression medium (Gibco®, Thermo Fisher Scientific) in vented Erlenmeyer flasks (Corning) at 120 rpm, in a 37 °C, 5% CO2, humidified incubator. Cells were transiently transfected in flasks using Lipofectamine 2000 (LifeTechnologies) according to the manufacturer's manual. 1 or 2 days before transfection, cells were seeded in fresh culture medium at  $0.5\times10^6$  cells/mL. When the density reached approximately  $1\times10^6$ cells/ml the cells were transfected. DNA was added to Lipofectamine 2000 in a 1:2.5 ratio, incubated at room temperature for 25min and added to the cells. Supernatants were recovered 3 days post transfection by centrifugation at 1500  $\times$  g, 10 min at 4 °C. cOmplete™ EDTA-free Protease Inhibitor Cocktail (Roche Diagnostics) was added to the cleared supernatant prior to storage at −20 °C.

*Purifcation of culture supernatants.* Supernatants were pre-conditioned by the addition of sodium chloride, calcium chloride and imidazole to give fnal concentrations of 500mM, 3mM and 10mM respectively. His-tagged proteins were extracted from the medium by afnity purifcation by loading the supernatants onto a 1 ml His GraviTrap prepacked columns (GE Healthcare), pre-equilibrated with 20 column volumes (CV) of 500 mM sodium chloride, 3 mM calcium chloride and 10 mM imidazole, 20 mM Tris-Cl pH8.0. The columns were then washed with 20 CV of the same buffer to remove non-specifically bound material. The second wash of the affinity columns was performed with the same bufer with increased imidazole concentration (12.5mM). Proteins were eluted with 10 column volumes of the same bufer with 100 mM imidazole. Eluted proteins were concentrated and injected onto a Superdex™ 200 Increase 10/300 GL column (GE Healthcare) that had been equilibrated with gel fltration bufer (150mM NaCl, 3mM CaCl2, 10mM Tris-Cl, pH8.0). Afer analysis of peak fractions by SDS-PAGE, proteins were concentrated at concentrations ranging from 2 to 6mg/ml.

**Bacterial protein production.** *Construction of plasmids expressing His-Ad3K and His-Ad3K/ MBP-DSG2*. Coding sequence of the HAd3 fbre knob (Asn124 to Asp319 of the full-length protein, Genbank: ABB17809.1) was amplified from pQE-Ad3knob<sup>13</sup>. The PCR fragments were cloned into the pETDuet-1 plasmid (Novagen), downstream an N-terminal hexa histidine tag, for either single or co-expression use.

Coding sequences for human DSG2-cadherin domains EC2-3 and EC3 were amplifed from the plasmid pHL-sec-DSG2 EC1-4 by PCR and introduced into the pETM-40 vector (EMBL), downstream of the maltose binding protein (MBP) gene. The sequences encoding the MBP/DSG2 EC2-3 or MBP/DSG2 EC3 fusion proteins were then amplifed and cloned into the second multiple cloning site of the pETDuet-1 plasmid already encoding the HAd3 knob.

*Expression and purification of His-Ad3K and His-Ad3K/MBP-DSG2.* For protein expression, *E*. *coli* Rosetta™(DE3)pLysS cells (Novagen) were transformed with pETDuet-Ad3K, pETDuet-Ad3K/DSG2 EC2-3 or pETDuet-Ad3K/DSG2 EC3 vectors. A single colony was inoculated into LB medium containing carbenicillin (50 µg.mL−1) and chloramphenicol (34 µg.mL−1) and grown overnight at 37 °C. Te culture was subsequently diluted to 1/100th into LB medium supplemented with carbenicillin and chloramphenicol. Bacteria were grown until OD600 reached 0.4–0.6. To induce protein expression, 1 mM of isopropyl β-D-1-thiogalactopyranoside was added to the culture which was transferred to 18°C. Afer 18h cells were harvested by centrifugation at 6,000g for 15 min. Pelleted bacteria were resuspended in lysis buffer (500 mM NaCl, 3 mM CaCl<sub>2</sub>, 10 mM Imidazole, 20 mM Tris-Cl, pH8.0 and cOmplete<sup>™</sup> EDTA-free Protease Inhibitor Cocktail) and lysed by sonication at 4 °C for 5 minutes 500ms pulse. Cell debris was spun down afer a centrifugation step at 39,200g (JA20 rotor) for 30min at 4°C.

Clarifed supernatants were then loaded onto a 1ml His GraviTrap prepacked column (GE Healthcare) equilibrated with 20 CV of 500mM sodium chloride, 3mM calcium chloride and 10mM imidazole, 20mM, Tris-Cl pH8.0. The column was washed with 10 CV of equilibration buffer and proteins were eluted with the same buffer containing 200mM imidazole.

Fractions containing the His-Ad3K/MBP-DSG2 EC2-3 or His-Ad3K/MBP-DSG2 EC3 complexes were pooled and treated 48h at room temperature with Tobacco Etch Virus (TEV) protease at a ratio of 1:20 (w/w) during the dialysis step. To remove the cleaved Maltose Binding Protein (MBP), the His-Ad3K/DSG2 EC2-3 or His-Ad3K/ DSG2 EC3 complexes were loaded again onto a 1 ml His GraviTrap prepacked column (GE Healthcare) and eluted as described above.

His-Ad3K alone, His-Ad3K/DSG2 EC2-3 and His-Ad3K/DSG2 EC3 complexes were further injected onto a Superdex<sup>™</sup> 200 Increase 10/300 GL column (GE Healthcare) that had been equilibrated with gel filtration buffer (150mM NaCl, 3mM CaCl2, 10mM Tris-Cl pH8.0). Afer analysis of peak fractions by SDS-PAGE, proteins were concentrated at concentrations ranging from 3 to 7mg/ml.

**Surface Plasmon Resonance binding experiments (SPR).** Surface plasmon resonance binding experiments were performed at 25 °C using a BIAcore 3000 instrument (GE Healthcare) equipped with a CM4 sensor chip (GE Healthcare). DSG2 EC1-4, DSG2 EC1-2, DSG2 EC3-4 were diluted to 10 μg/ml in 10mM sodium acetate, pH 4.5, and immobilized (3000-4000 RU) in 10 mM HEPES, 145 mM NaCl, 2 mM CaCl<sub>2</sub>, 0.005% surfactant P20, pH 7.4 (HBS-P calcium buffer) using the amine coupling chemistry according to the manufacturer instructions (GE Healthcare). Increasing concentrations of Pt-Dd were injected over the captured surfaces and binding was measured in HBS-P calcium buffer at a flow rate of 15  $\mu$ l/min. Surfaces were regenerated by pulse injections of 5mM EDTA.

Analysis of protein-protein interactions by Size Exclusion Chromatography (SEC). The interaction between Ad3K and DSG2 was investigated by size exclusion chromatography. The proteins were mixed in a 3:1 ratio (3 monomeric DSG2 to 1 trimeric Ad3K) in gel fltration bufer (150mM NaCl, 3mM CaCl2, 10mM Tris-Cl pH8.0) and incubate overnight at 4 °C. The interaction of the proteins was analysed on a Superdex™ 200 Increase 10/300 GL column (GE Healthcare). The samples were centrifuged (3 min, 4 °C, 12,000  $\times$  g) and loaded onto the column using a 0.5 mL injection loop. The flow rate was 0.4 mL/min and the elution profile of the proteins was recorded at both 280 and 260nm.

**Negative-stain electron microscopy.** The standard mica-carbon preparation was used with sample at 50 ng/ml. Grids were stained by Uranyl acetate and observed at 100 kV on a Tecnai T12 microscope. 2D class averages were calculated by 2 cycles of classifcation from 13.143 and 13.149 original particles for Ad3K and Ad3K+EC2-3, respectively.

**Size Exclusion Chromatography coupled to Multi-Angle Laser Light Scattering experiments (SEC-MALLS).** SEC-MALLS experiments were performed using a A DAWN-Heleos II detector (Wyatt Technology) with a 690-nm wavelength laser in combination with an Optilab T-rEX Refractive index detector (Wyatt Technology). 50 <sup>μ</sup>L of His-Ad3K/DSG2 EC2-3 at 1mg/mL was injected over a Superdex™ 200 Increase 10/300 GL column (GE Healthcare) pre-equilibrated with gel fltration bufer (150 mM NaCl, 3 mM CaCl2, 10mM Tris-Cl pH8.0) at 0.5mL/min. A value of 0.185mL/g was assumed for the dn/dc ratio of the protein. Astra sofware (Wyatt Technology) was used to analyze the data and to determine the weight-averaged molar masses (Mw).

**Sedimentation Equilibrium by Analytical Ultracentrifugation Experiments (SE-AUC).** Sedimentation velocity (SV) experiments were performed on a Beckman Coulter XL-I analytical ultracentrifuge with a An50Ti rotor. 3 mm or 12 mm pathlength 2-sector centerpieces cells, equipped with sapphire windows, were flled with 150 ul or 450 ul of sample respectively and centrifuged at 42,000 rpm at 20 °C. Sedimentation profles were acquired using absorbance at 280nm and interference optics.

Analysis and ftting of the data was performed using the sofware SedFit and Gussi. All s values obtained with the c(s) distribution in 3mM CaCl2, 10mM Tris pH 8.0, 150mM NaCl were converted to s20,W with SEDNTERP (version 20130813 Beta) using the measured density (1.005 g/ml) and viscosity (1.019 cp) of this bufer.

#### **References**

- 1. Wickham, T. J., Mathias, P., Cheresh, D. A. & Nemerow, G. R. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. *Cell* **73**, 309–319 (1993).
- 2. Bergelson, J. M. *et al*. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. *Science* **275**, 1320–1323  $(1997)$
- 3. Roelvink, P. W. *et al*. Tecoxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F. *J. Virol.* **72**, 7909–7915 (1998).
- 4. Gaggar, A., Shayakhmetov, D. M. & Lieber, A. CD46 is a cellular receptor for group B adenoviruses. *Nat. Med.* **9**, 1408–1412 (2003). 5. Tuve, S. *et al*. A new group B adenovirus receptor is expressed at high levels on human stem and tumor cells. *J. Virol.* **80**, 12109–12120
- $(2006)$ 6. Wang, H. *et al*. Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. *Nat. Med.* **17**, 96–104 (2011).
- 7. Trinh, H. V. *et al*. Avidity binding of human adenovirus serotypes 3 and 7 to the membrane cofactor CD46 triggers infection. *J. Virol.* **86**, 1623–1637 (2012).
- 8. Fender, P., Ruigrok, R. W., Gout, E., Bufet, S. & Chroboczek, J. Adenovirus dodecahedron, a new vector for human gene transfer. *Nat. Biotechnol.* **15**, 52–56 (1997).
- 9. Fender, P., Hall, K., Schoehn, G. & Blair, G. E. Impact of human adenovirus type 3 dodecahedron on host cells and its potential role in viral infection. *J. Virol.* **86**, 5380–5385 (2012).
- 10. Louis, N., Fender, P., Barge, A., Kitts, P. & Chroboczek, J. Cell-binding domain of adenovirus serotype 2 fber. *J. Virol.* **68**, 4104–4106 (1994).
- 11. Bewley, M. C., Springer, K., Zhang, Y. B., Freimuth, P. & Flanagan, J. M. Structural analysis of the mechanism of adenovirus binding to its human cellular receptor, CAR. *Science* **286**, 1579–1583 (1999).
- 12. Persson, B. D. *et al*. Adenovirus type 11 binding alters the conformation of its receptor CD46. *Nat. Struct. Mol. Biol.* **14**, 164–166 (2007).
- 13. Wang, H. *et al*. Structural and functional studies on the interaction of adenovirus fber knobs and desmoglein 2. *J. Virol.* **87**, 11346–11362 (2013).
- 14. Awad, M. M. *et al*. DSG2 mutations contribute to arrhythmogenic right ventricular dysplasia/cardiomyopathy. *Am. J. Hum. Genet.* **79**, 136–142 (2006).
- 15. Syed, S.-H. *et al*. Molecular interactions between desmosomal cadherins. *Biochem. J.* **362**, 317–327 (2002).
- 16. Harrison, O. J. *et al*. Structural basis of adhesive binding by desmocollins and desmogleins. *Proc. Natl. Acad. Sci. USA* **113**, 7160–7165 (2016).
- 17. Cai, F. *et al*. Desmoglein-2 is overexpressed in non-small cell lung cancer tissues and its knockdown suppresses NSCLC growth by regulation of p27 and CDK2. *J*. *Cancer Res*. *Clin*. *Oncol*. [https://doi.org/10.1007/s00432-016-2250-0](http://dx.doi.org/10.1007/s00432-016-2250-0). (2016).
- 18. Kurzen, H., Münzing, I. & Hartschuh, W. Expression of desmosomal proteins in squamous cell carcinomas of the skin. *J. Cutan. Pathol.* **30**, 621–630 (2003).
- 19. Strauss, R. *et al*. Epithelial phenotype confers resistance of ovarian cancer cells to oncolytic adenoviruses. *Cancer Res.* **69**, 5115–5125 (2009).
- 20. Strauss, R. & Lieber, A. Anatomical and physical barriers to tumor targeting with oncolytic adenoviruses *in vivo*. *Curr. Opin. Mol. Ter.* **11**, 513–522 (2009).
- 21. Wang, H. *et al.* Multimerization of adenovirus serotype 3 fiber knob domains is required for efficient binding of virus to desmoglein 2 and subsequent opening of epithelial junctions. *J. Virol.* **85**, 6390–6402 (2011).
- 22. Lu, Z.-Z. *et al*. Penton-dodecahedral particles trigger opening of intercellular junctions and facilitate viral spread during adenovirus serotype 3 infection of epithelial cells. *PLoS Pathog.* **9**, e1003718 (2013).
- 23. Beyer, I. *et al*. Epithelial junction opener JO-1 improves monoclonal antibody therapy of cancer. *Cancer Res.* **71**, 7080–7090 (2011).
- 24. Richter, M. et al. Preclinical safety and efficacy studies with an affinity-enhanced epithelial junction opener and PEGylated liposomal doxorubicin. *Mol. Ther. Methods Clin. Dev.* 2, 15005 (2015).
- 25. Kamekura, R. *et al*. Infammation-induced desmoglein-2 ectodomain shedding compromises the mucosal barrier. *Mol. Biol. Cell* **26**, 3165–3177 (2015).
- 26. Wang, H. *et al*. Intracellular Signaling and Desmoglein 2 Shedding Triggered by Human Adenoviruses Ad3, Ad14, and Ad14P1. *J. Virol.* **89**, 10841–10859 (2015).
- 27. Koski, A. *et al*. Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. *Mol. Ter. J. Am.*  Soc. Gene Ther. 18, 1874-1884 (2010).
- 28. Hemminki, O. et al. Oncolytic adenovirus based on serotype 3. Cancer Gene Ther. 18, 288-296 (2011).
- 29. Hemminki, O. *et al*. Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer. *Mol. Ther. I. Am. Soc. Gene Ther.* **20.** 1821–1830 (2012).
- 30. Mateo, M., Generous, A., Sinn, P. L. & Cattaneo, R. Connections matter–how viruses use cell–cell adhesion components. *J. Cell Sci.* **128**, 431–439 (2015).
- 31. Walters, R. W. *et al*. Adenovirus fber disrupts CAR-mediated intercellular adhesion allowing virus escape. *Cell* **110**, 789–799 (2002).
- 32. Chitaev, N. A. & Troyanovsky, S. M. Direct Ca2+-dependent heterophilic interaction between desmosomal cadherins, desmoglein and desmocollin, contributes to cell-cell adhesion. *J. Cell Biol.* **138**, 193–201 (1997).
- 33. Burmeister, W. P., Guilligay, D., Cusack, S., Wadell, G. & Arnberg, N. Crystal structure of species D adenovirus fber knobs and their sialic acid binding sites. *J. Virol.* **78**, 7727–7736 (2004).
- 34. Nilsson, E. C. et al. The GD1a glycan is a cellular receptor for adenoviruses causing epidemic keratoconjunctivitis. *Nat. Med.* 17, 105–109 (2011).
- 35. Wang, H. *et al*. A new human DSG2-transgenic mouse model for studying the tropism and pathology of human adenoviruses. *J. Virol.* **86**, 6286–6302 (2012).
- 36. Aricescu, A. R., Lu, W. & Jones, E. Y. A time- and cost-efcient system for high-level protein production in mammalian cells. *Acta Crystallogr. D Biol. Crystallogr.* **62**, 1243–1250 (2006).

#### **Acknowledgements**

Tis work used the platforms of the Grenoble Instruct center (ISBG; UMS 3518 CNRS-CEA-UJF-EMBL) with support from FRISBI (ANR-10-INSB-05-02) and GRAL (ANR-10-LABX-49-01) within the Grenoble Partnership for Structural Biology (PSB). We are particularly grateful to Caroline Mas, Luca Signor and Aline Le-Roy for the MALLS, MS and AUC studies and to Daphna Fenel, Guy Schoehn and Emmanuelle Neumann for the TEM and class averages pictures. MM was supported by a M2 scholarship awarded by the Labex GRAL. We thank the CNRS for long-lasting support and the PICS traveling grant.

#### **Author Contributions**

A.L. and P.F. supervised the project. E.V.S., F.I. and C.Z. designed the experiments. E.V.S., M.M., C.D., C.V. and H.W. performed the experiments.

#### **Additional Information**

**Supplementary information** accompanies this paper at [https://doi.org/10.1038/s41598-018-26871-x](http://dx.doi.org/10.1038/s41598-018-26871-x).

**Competing Interests:** The authors declare no competing interests.

**Publisher's note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional afliations.

**T** Open Access This article is licensed under a Creative Commons Attribution 4.0 International  $\left[$ cc) License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit [http://creativecommons.org/licenses/by/4.0/.](http://creativecommons.org/licenses/by/4.0/)

 $© The Author(s) 2018$